Literature DB >> 27206569

Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Jodi J Weinstein1, Muhammad O Chohan2, Mark Slifstein3, Lawrence S Kegeles3, Holly Moore4, Anissa Abi-Dargham3.   

Abstract

In light of the clinical evidence implicating dopamine in schizophrenia and the prominent hypotheses put forth regarding alterations in dopaminergic transmission in this disease, molecular imaging has been used to examine multiple aspects of the dopaminergic system. We review the imaging methods used and compare the findings across the different molecular targets. Findings have converged to suggest early dysregulation in the striatum, especially in the rostral caudate, manifesting as excess synthesis and release. Recent data showed deficit extending to most cortical regions and even to other extrastriatal subcortical regions not previously considered to be "hypodopaminergic" in schizophrenia. These findings yield a new topography for the dopaminergic dysregulation in schizophrenia. We discuss the dopaminergic innervation within the individual projection fields to provide a topographical map of this dual dysregulation and explore potential cellular and circuit-based mechanisms for brain region-dependent alterations in dopaminergic parameters. This refined knowledge is essential to better guide translational studies and efforts in early drug development.
Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cortex; Dopamine; Neuroanatomy; PET imaging; Schizophrenia; Striatum

Mesh:

Substances:

Year:  2016        PMID: 27206569      PMCID: PMC5177794          DOI: 10.1016/j.biopsych.2016.03.2104

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  127 in total

1.  A reversible tracer analysis approach to the study of effective dopamine turnover.

Authors:  V Sossi; D J Doudet; J E Holden
Journal:  J Cereb Blood Flow Metab       Date:  2001-04       Impact factor: 6.200

2.  Histochemically distinct compartments in the striatum of human, monkeys, and cat demonstrated by acetylthiocholinesterase staining.

Authors:  A M Graybiel; C W Ragsdale
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

3.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Authors:  M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

4.  Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Authors:  Lawrence S Kegeles; Mark Slifstein; Xiaoyan Xu; Nina Urban; Judy L Thompson; Tiffany Moadel; Jill M Harkavy-Friedman; Roberto Gil; Marc Laruelle; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2010-07-31       Impact factor: 13.382

5.  Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects.

Authors:  J K Zubieta; S F Taylor; P Huguelet; R A Koeppe; M R Kilbourn; K A Frey
Journal:  Biol Psychiatry       Date:  2001-01-15       Impact factor: 13.382

6.  Increased stress-induced dopamine release in psychosis.

Authors:  Romina Mizrahi; Jean Addington; Pablo M Rusjan; Ivonne Suridjan; Alvina Ng; Isabelle Boileau; Jens C Pruessner; Gary Remington; Sylvain Houle; Alan A Wilson
Journal:  Biol Psychiatry       Date:  2011-11-30       Impact factor: 13.382

7.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

8.  Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.

Authors:  J Lavalaye; D H Linszen; J Booij; P M Dingemans; L Reneman; J B Habraken; B P Gersons; E A van Royen
Journal:  Schizophr Res       Date:  2001-01-15       Impact factor: 4.939

9.  Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride.

Authors:  Patrizia Riccardi; Ron Baldwin; Ronald Salomon; Sharlet Anderson; Mohammad S Ansari; Rui Li; Benoit Dawant; Amy Bauernfeind; Dennis Schmidt; Robert Kessler
Journal:  Biol Psychiatry       Date:  2007-06-27       Impact factor: 13.382

10.  Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1.

Authors:  Mei-Chun Hsiao; Kun-Ju Lin; Chia-Yih Liu; Kai-Yuan Tzen; Tzu-Chen Yen
Journal:  Schizophr Res       Date:  2003-12-01       Impact factor: 4.939

View more
  89 in total

Review 1.  The neuroanatomic complexity of the CRF and DA systems and their interface: What we still don't know.

Authors:  E A Kelly; J L Fudge
Journal:  Neurosci Biobehav Rev       Date:  2018-04-25       Impact factor: 8.989

2.  Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum.

Authors:  Christin Schifani; Sina Hafizi; Huai-Hsuan Tseng; Cory Gerritsen; Miran Kenk; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi
Journal:  Schizophr Res       Date:  2018-11-06       Impact factor: 4.939

3.  Diurnal rhythms across the human dorsal and ventral striatum.

Authors:  Kyle D Ketchesin; Wei Zong; Mariah A Hildebrand; Marianne L Seney; Kelly M Cahill; Madeline R Scott; Vaishnavi G Shankar; Jill R Glausier; David A Lewis; George C Tseng; Colleen A McClung
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

4.  Striatal dopamine D2 receptors regulate effort but not value-based decision making and alter the dopaminergic encoding of cost.

Authors:  Ina Filla; Matthew R Bailey; Elke Schipani; Vanessa Winiger; Chris Mezias; Peter D Balsam; Eleanor H Simpson
Journal:  Neuropsychopharmacology       Date:  2018-07-20       Impact factor: 7.853

Review 5.  Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

Authors:  Colm M P O'Tuathaigh; Paula M Moran; Xuechu C Zhen; John L Waddington
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

Review 6.  Stress during critical periods of development and risk for schizophrenia.

Authors:  Felipe V Gomes; Xiyu Zhu; Anthony A Grace
Journal:  Schizophr Res       Date:  2019-01-30       Impact factor: 4.939

7.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 8.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

9.  A Perceptual Inference Mechanism for Hallucinations Linked to Striatal Dopamine.

Authors:  Clifford M Cassidy; Peter D Balsam; Jodi J Weinstein; Rachel J Rosengard; Mark Slifstein; Nathaniel D Daw; Anissa Abi-Dargham; Guillermo Horga
Journal:  Curr Biol       Date:  2018-02-02       Impact factor: 10.834

10.  Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia.

Authors:  Francesca Managò; Maddalena Mereu; Surjeet Mastwal; Rosa Mastrogiacomo; Diego Scheggia; Marco Emanuele; Maria A De Luca; Daniel R Weinberger; Kuan Hong Wang; Francesco Papaleo
Journal:  Cell Rep       Date:  2016-08-11       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.